IMMUNOCORE HLDGS ADS/1 Asset Resilience Ratio
IMMUNOCORE HLDGS ADS/1 asset resilience ratio. IMMUNOCORE HLDGS ADS/1 (6YG) has an Asset Resilience Ratio of 35.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IMMUNOCORE HLDGS ADS/1 defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of IMMUNOCORE HLDGS ADS/1 (2023–2025)
Asset resilience ratio of IMMUNOCORE HLDGS ADS/1 from 2023 to 2025. This chart shows how IMMUNOCORE HLDGS ADS/1's Asset Resilience Ratio has changed over time. Read 6YG current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down IMMUNOCORE HLDGS ADS/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 6YG total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €395.29 Million | 35.31% |
| Total Liquid Assets | €395.29 Million | 35.31% |
Asset Resilience Insights
- Very High Liquidity: IMMUNOCORE HLDGS ADS/1 maintains exceptional liquid asset reserves at 35.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
IMMUNOCORE HLDGS ADS/1 Industry Peers by Asset Resilience Ratio
Compare IMMUNOCORE HLDGS ADS/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
IMMUNOCORE HLDGS ADS/1 Asset Resilience Ratio by Year (2023–2025)
IMMUNOCORE HLDGS ADS/1 asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for IMMUNOCORE HLDGS ADS/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.15% | €396.44 Million ≈ $463.48 Million |
€1.07 Billion ≈ $1.25 Billion |
+1.02pp |
| 2024-12-31 | 36.12% | €364.64 Million ≈ $426.31 Million |
€1.01 Billion ≈ $1.18 Billion |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€597.00 Million ≈ $697.96 Million |
-- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more